IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer - OncLive
3/20/2022 12:00:00 AM3 years 11 months ago
by Gina Mauro
by Gina Mauro
The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The use of intraperitoneal (IP) carboplatin with paclitaxel improved progression-free survival (PFS), but not overall survival (OS), vs intravenous (IV) chemotherapy in patients with epithelial ovari… [+8391 chars]
full article...